You haven't found one company to compare with IPIX because IMO there has not been a company to date with the power of our pipeline that has had 3 drugs with so many multi-billion dollar indications and with the clinical data leading one to believe all could become first-in-class drugs.
To use my horse analogy, should Secretariat have been valued as any other decent thoroughbred or was he so much better than anything before that he set a new standard for value?
Same goes w/ IPIX. We have a number of BPs wanting our products. I am sure a few will bid up to secure our pipeline and it will have to be far and away what has been paid prior to now.
On my side, I have outstanding results for Brilacidin in OM, UC and when put in pill form most likely all IBD problems, and as an antibiotic. We have Psoriasis for Prurisol and most likely major value in topical creams for dermatologic conditions (B also has major dermatology applications). Prurisol also has potential to work on all autoimmune diseases. Kevetrin could be the foundational pill to work with all other cancer treatments and is the first to show a direct activation of the p53 pathway.
If BPs don't want to pony up the correct $$ now, then don't sell the company. Partner out enough to garner $$ so that we can further advance our drugs and greatly enhance their value.
Biotech is like IT, things change fast and what was the norm yesterday is quickly changed. Thus, I expect IPIX to forge a new pathway in biotech as to value.
I expect IPIX to do to biotech what the Fosbury Flop did to high jumping - it set a whole new paradigm on how the game is played.
To use my horse analogy, should Secretariat have been valued as any other decent thoroughbred or was he so much better than anything before that he set a new standard for value?
Same goes w/ IPIX. We have a number of BPs wanting our products. I am sure a few will bid up to secure our pipeline and it will have to be far and away what has been paid prior to now.
On my side, I have outstanding results for Brilacidin in OM, UC and when put in pill form most likely all IBD problems, and as an antibiotic. We have Psoriasis for Prurisol and most likely major value in topical creams for dermatologic conditions (B also has major dermatology applications). Prurisol also has potential to work on all autoimmune diseases. Kevetrin could be the foundational pill to work with all other cancer treatments and is the first to show a direct activation of the p53 pathway.
If BPs don't want to pony up the correct $$ now, then don't sell the company. Partner out enough to garner $$ so that we can further advance our drugs and greatly enhance their value.
Biotech is like IT, things change fast and what was the norm yesterday is quickly changed. Thus, I expect IPIX to forge a new pathway in biotech as to value.
I expect IPIX to do to biotech what the Fosbury Flop did to high jumping - it set a whole new paradigm on how the game is played.
6
